Predicting air passenger traffic during Covid-19 & its economic impact

Most governments have implemented restrictive policies in response to the global coronavirus outbreak to curb the pandemic and reduce the number of deaths. Air traffic suspension is one of the most important restrictive policies in terms of reducing global migration for short period, though it has major and long term impact on all economies of the world.The objective of this study is to analyse the impact global air travel ban on various aviation sectors. This required authors to collect and pre-process the passengers traffic worldwide via flights. Based on historical data from 1970 till 2019 (Source- data.worldbank.org), a predictive model is prepared and implemented to get a clear picture of the losses faced by the aviation sector in terms of air passenger traffic. Further we will be comparing the forecasted values with the real time values in order to study the effect of air travel ban on aviation and its supported sectors. In addition, a study of the economic impact of the air travel bans and the cumulative impact of the Covid-19 pandemic is being conducted by looking at real GDP levels (in percentages) and future estimates, measuring them all in percentages for the world economy and various industrialized countries, developed markets, and developing nations, and a comparison being made and then further analyzing them. In the near term, some countries will be more affected than others, and most airline businesses will lose because of the travel ban. We hope that these early findings will aid in the development of informed policies and exit plans for this global crisis. © 2022 Author(s).

A Systematic Review and Meta-Analysis of an Emerging Therapy against COVID-19: Is Convalescent Plasma a Hidden Gem Not Yet Optimized?

Background: An unprecedented global effort in identifying potentially viable and emerging drugs for effective treatment of the novel coronavirus disease (2019) is being made. Of the most promising candidate therapies, convalescent plasma (CP), albeit controversial, is approved for emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA). The concept rests on passive immunity, achieved by administering plasma with high titers of neutralizing antibodies to reduce severity of SARS-CoV-2 infection and mortality. The aim of this paper is to assess the clinical improvement, patients' discharge status and all-cause mortality in convalescent plasma versus standard of care COVID-19 patient groups. Methods: Using PRISMA guidelines, a review was conducted from January, 2020, until October, 2020 employing keywords including "convalescent plasma", "clinical improvement, "mortality", "adverse events", "viral load", "dosing", and survival." Dichotomous data for all-cause mortality, patients' discharge status, and clinical improvement at day 14 of treatment were meta-analyzed applying the Mantel-Haenszel (M-H) random effects model using Review Manager 5.4. Results: A total of 627 (23.9%) patients in the CP group and 1997 (76.1%) patients in the control group were pooled. The studies were conducted in the United States, China, Netherlands, and Iran. The CP group had a lower association to all-cause mortality as compared to the control group [OR: 0.69;CI: 0.50 to 0.96;P=0.03]. Patients who received CP had higher probability of discharge during the study course [OR: 1.87;CI: 1.1 to 3.18;P=0.02]. Bias was expected in the analysis due to the stratified of study designs included. Conclusion: Convalescent plasma therapy may be an effective and vital tool with promising historical, current, and expected clinical trial evidence of metrics such as increased safety and reduction of all-cause mortality.